GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.08 USD | +0.07% |
|
-0.34% | -17.20% |
| Apr. 24 | HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69 | MT |
| Apr. 23 | Argus Cuts Price Target on Gilead Sciences to $75 From $85 | MT |
Financials (USD)
| Sales 2024 * | 27.5B | Sales 2025 * | 27.99B | Capitalization | 83.58B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.73B | Net income 2025 * | 6.88B | EV / Sales 2024 * | 3.55 x |
| Net Debt 2024 * | 14.01B | Net Debt 2025 * | 8.43B | EV / Sales 2025 * | 3.29 x |
| P/E ratio 2024 * |
30.1
x | P/E ratio 2025 * |
12.2
x | Employees | 18,000 |
| Yield 2024 * |
4.68% | Yield 2025 * |
4.88% | Free-Float | 99.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | +0.07% | ||
| 1 week | -0.34% | ||
| Current month | -8.42% | ||
| 1 month | -7.62% | ||
| 3 months | -15.60% | ||
| 6 months | -13.51% | ||
| Current year | -17.20% |
1 week
65.90
67.68
1 month
65.9073.87
Current year
65.9087.87
1 year
65.9087.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 215 M€ | +11.68% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 67.08 | +0.07% | 8,265,653 |
| 24-04-23 | 67.03 | +0.12% | 5,240,249 |
| 24-04-22 | 66.95 | +0.28% | 5,622,367 |
| 24-04-19 | 66.76 | +0.91% | 10,657,002 |
| 24-04-18 | 66.16 | -1.15% | 6,442,224 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
04:02pm
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
67.08
USD
Average target price
84.95
USD
Spread / Average Target
+26.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.20% | 83.58B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- GILD Stock
